Equities Analysts Issue Forecasts for Hikma Pharmaceuticals PLC’s FY2026 Earnings (OTCMKTS:HKMPF)

Hikma Pharmaceuticals PLC (OTCMKTS:HKMPF – Get Rating) – Stock analysts at Jefferies Financial Group issued their FY2026 earnings per share estimates for Hikma Pharmaceuticals in a research note issued to investors on Friday, May 20th. Jefferies Financial Group analyst J. Vane-Tempest forecasts that the company will post earnings of $2.37 per share for the year.

Other research analysts have also recently issued research reports about the stock. Zacks Investment Research cut shares of Hikma Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, May 4th. JPMorgan Chase & Co. decreased their price objective on shares of Hikma Pharmaceuticals from GBX 3,000 ($37.75) to GBX 2,900 ($36.49) in a report on Wednesday, March 2nd. Finally, Morgan Stanley decreased their price objective on shares of Hikma Pharmaceuticals from GBX 2,300 ($28.94) to GBX 2,100 ($26.43) in a report on Friday, May 6th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $1,677.00.

OTCMKTS HKMPF opened at $20.82 on Monday. Hikma Pharmaceuticals has a 52 week low of $20.82 and a 52 week high of $37.70. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.38 and a current ratio of 2.06. The company has a 50-day moving average price of $25.55 and a two-hundred day moving average price of $27.39.

About Hikma Pharmaceuticals (Get Rating)

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded.

Recommended Stories